Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zongertinib drug-drug interaction study with dabigatran and drug cocktail
NCT06504862Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2024
- Primary completion
- Oct 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of zongertinib (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of Dabigatran in Plasma Over the Time Interval From 0 Extrapolated to Infinity at 48 hours, Maximum Measured Concentration of Dabigatran in Plasma at 48 hours and 6 more. Started Aug 2024; status: completed.
02
Drugs
zongertinib
Beyond the preview
Go deeper on NCT06504862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06504862.